Bristol-Myers Squibb’s ORENCIA® (abatacept) Receives Second European Commission Approval in Less than a Year – New Approval for Treatment of Active Psoriatic Arthritis (PsA)1

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. SPCX
4. ACN
5. IBM
6. TSLA
7. DPZ
8. NVDA
9. PRIM
10. META

Go back to Bristol-Myers Squibb’s ORENCIA® (abatacept) Receives Second European Commission Approval in Less than a Year – New Approval for Treatment of Active Psoriatic Arthritis (PsA)1

Bristol-Myers Squibb Co. (BMY) PT Lowered to $61 at Leerink Partners

July 28, 2017 10:31 AM EDT

Leerink Partners lowered its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $61.00 (from $66.00) while maintaining a Outperform rating following the company's 2Q. BMY delivered in line earnings of 74c.

Analyst Seamus Fernandez now forecasts a 9% EPS growth in 2018-22E excluding Opdivo +... More

Bristol-Myers Squibb's (BMY) Call Didn't Alleviate Concerns - BMO

July 27, 2017 12:38 PM EDT

BMO Capital analyst Alex Arfaei said they do not believe Bristol-Myers Squibb's (NYSE: BMY) call alleviated the market's increased concerns about CM-227 following MSYTIC's failure. The firm maintained an Underperform rating and price target of $51.

"We estimate that by the end of... More